(A) Reverse-transcription PCR products for Tph2 and Sert in E14.5 mouse pancreata.
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Appendix Figure S1 Determinants of psychostimulant sensitivity in pancreatic islets.
(A) Reverse-transcription PCR products for Tph2 and Sert in E14.5 mouse pancreata.
(B) Prenatal drug exposure does not affect glucagon immunoreactivity at birth (P0). Data from triplicate experiments shown as means ± s.d. 3 Appendix Figure S2 Psychostimulants decrease insulin expression in cultured embryonic pancreas.
(A) To verify that pancreas explants (Serafimidis et al., 2017) are appropriate as a cellular model of psychostimulant effects, we exposed such explants to amphetamine (10 µM), cocaine (10 µM), methamphetamine (10 µM) or 5-HT (500 nM) for 3 days in vitro, mimicking the in vivo drug-treatment paradigm. (overall drug effect by ANOVA: F (4,23) = 6.93, p = 0.0008; A1) Not only amphetamine (p < 0.01) and methamphetamine (p < 0.001) but also exogenous 5-HT (p < 0.001) reduced intracellular insulin content significantly. These data suggest that disrupted 5-HT signaling (note that psychoactive drugs do not induce long-lasting 5-HT accumulation intracellularly; data not shown) either enhances the release of insulin or instead impairs its expression through a transcriptional program. Data were expressed as means ± s.d. Scale bars = 20 μm and 6 μm (insets). 4 Appendix Figure S3 Generation of SERT (Slc6a4) null offspring.
We crossed Slc6a4 Cre/+ heterozygous knock-in mice (Zhuang et al., 2005) to produce phenotypically SERT null offspring. This strategy allowed us to directly compare littermates carrying different Slc6a4 genotypes. Here, a representative Western blot on the loss of SERT protein is shown with n ≥ 4 mice/genotype. Note that heterozygous mice (M01-M06) have halved SERT protein content in their cerebral cortex. Numbers are internal mouse identifiers. β-Actin was used as loading control. Data on SERT lossof-function in Slc6a4 Cre/Cre mice have been published elsewhere (Reisinger et al., 2019) . 5 Appendix Figure S4 Prenatal psychostimulant exposure does not affect islet composition, glucagon content, body weight but does so for insulin + β cells at 1-year of age.
(A) Prenatal exposure to psychostimulants did not affect β and α cell numbers in the pancreas of 6-week old mice (β cells: F (3,19) = 1.029, p = 0.402; α cells: F (3,19) = 0.53, p = 0.668). (B) Prenatal exposure to psychostimulants did not affect glucagon immunoreactivity in the pancreata of either female or male (6-week old) offspring. Data were expressed as means ± s.d. from n ≥ 3 mice/group (except for amphetamine and cocaine in males; n = 1), one-way ANOVA. (C) Bodyweight of adult mice with in utero drug history. Data were expressed as means ± s.d. from n ≥ 3 mice/group (one-way ANOVA for females: F (3,23) = 0.75, p = 0.533; for males: F (3,37) = 0.199, p = 0.896). (D) Intrauterine amphetamine exposure significantly increased the number of insulin + β cells in male but not female offspring (p < 0.05; n = 56 mice/group; Student's t-test). The number of α cells in this age group did not change as a factor of either amphetamine treatment or sex. 6 Appendix Figure S5 FEV expression and its relation to type 2 diabetes in humans.
(A) Transcriptome analysis (bulk) of human pancreatic islets for FEV in control vs.
patients with with type 2 diabetes (T2D). Data were expressed as log 2 counts per million (CPM) and normalized to control. (A1) Co-expression analysis of FEV vs. glucose tolerance status. Samples were stratified according to glucose tolerance estimated from HbA1c, i.e. donors with normal glucose tolerance (HbA1c < 6%, n = 114), impaired glucose tolerance (IGT, 6% ≤ HbA1c < 6.5%, n = 30) and T2D (HbA1c ≥ 6.5%, n = 24).
Single data points denote outliers. Boxes represent 25 th percentiles ± 90 th percentiles, horizontal lines correspond to median values. 7 Appendix Figure S6 SLC18A2 and SLC6A4 expression and their relation to type 2 diabetes in humans.
Transcriptome analysis (bulk) of human pancreatic islets for SLC18A2 (A) and SLC6A4 (B) in control vs. patients with with type 2 diabetes (T2D). Data were presented as log 2 counts per million (CPM), normalized to control. For subsequent analysis, all samples were stratified according to glucose tolerance estimated from HbA1c, i.e. donors with normal glucose tolerance (HbA1c < 6%, n = 114, black label in co-expression analysis), impaired glucose tolerance (IGT, 6% ≤ HbA1c < 6.5%, n = 30, blue label in coexpression analysis), and T2D (HbA1c ≥ 6.5%, n = 24, grey label in co-expression analysis). Co-expression analysis of SLC18A2 (A1) and SLC6A4 (B1) vs. glucose tolerance status. Single data points denote outliers. Boxes represent 25 th percentiles ± 90 th percentiles, horizontal lines represent median values. Co-expression analysis of SLC18A2 vs. INS (A2) or GCG (A3) and SLC6A4 vs. INS (B2) or GCG (B3).
